Inflammatory Disease Testing: Reading Magnitude, Not Just Presence
Quick Answer — Acute-phase proteins answer “how much systemic inflammation is there, and is it changing”. They do not answer “where” or “from what”. The clinical value comes from three uses: detecting a response that the examination missed, grading its severity, and tracking the response to treatment. A single value used as a diagnosis is the most common way these assays are wasted.
Quick Answer
Magnitude first, trend second, location never.
Species first, marker second
| Species | Dominant acute-phase protein | Practical implication |
|---|---|---|
| Dog | C-reactive protein (CRP) | CRP is the primary marker; interpret against a canine interval |
| Cat | Serum amyloid A (SAA) | SAA carries the response; CRP is a weaker signal in cats |
This is the single most consequential species difference in the inflammatory menu, and it is routinely ignored when clinics use one marker across both species.
What a value tells you, in three layers
Layer 1 — is there a systemic response? A value clearly above the interval says yes, at the time of sampling. A value inside the interval says no large response; it does not exclude localized disease.
Layer 2 — how severe? Magnitude correlates with the scale of the inflammatory process, which supports triage: a modest elevation in an ambulatory animal and a marked elevation in a collapsed one describe different clinical states, and the number is one input among several.
Layer 3 — is it resolving? This is where these assays earn their price. A falling value after appropriate therapy is evidence that the intervention worked; a flat or rising value in a clinically improving animal suggests an ongoing or second process.
Data pending. This section reports measured values from internal validation studies. They are published once the supporting study is complete; the current report is available from technical support on request.
Where the tests change management
| Scenario | Contribution |
|---|---|
| Pyrexia of unknown origin | A normal value redirects the differential away from systemic inflammation |
| Post-operative monitoring | A value that fails to fall suggests complication earlier than clinical signs |
| Sepsis suspicion | Magnitude supports triage; serial values support response assessment |
| Chronic enteropathy / cholangitis (cat) | SAA tracks the inflammatory component and responds to therapy |
| Monitoring immunosuppressive therapy | Trend supports dose decisions alongside clinical response |
| Pre-anaesthetic screening | Low yield unless a specific question exists |
The last row is a caution: routine pre-anaesthetic acute-phase testing rarely changes the anaesthetic plan.
Pairing markers across species
Where both are available, the feline pair (SAA with fPL) is more informative than either alone:
- High SAA, high fPL — pancreatitis with a systemic response; manage accordingly.
- High SAA, normal fPL — inflammation elsewhere; look at biliary tree, intestine, urinary tract.
- Normal SAA, high fPL — pancreatic involvement without systemic response.
Data pending. This section reports measured values from internal validation studies. They are published once the supporting study is complete; the current report is available from technical support on request.
What the assays do not do
- They do not localize. No acute-phase protein tells you which organ.
- They do not identify an organism. They are not a substitute for culture or cytology.
- They do not distinguish infectious from sterile inflammation. A sterile abscess and a bacterial infection can produce the same magnitude.
- They do not replace serial clinical assessment. A trend in a patient that is clinically unchanged warrants a second look at the trend, not an immediate escalation based on the number alone.
Six traps
- Using CRP as the feline marker. Understates the response in cats.
- Treating a single value as a diagnosis. It is a magnitude.
- Excluding disease on a normal value. Localized and chronic processes hide inside the interval.
- Changing platform mid-monitoring. Bias shift mimics clinical change.
- Ignoring the sampling interval. A re-check drawn too early sits inside assay noise.
- Acting on a trend that is smaller than the assay’s imprecision. The number moved; the patient did not.
The Author’s Take
Position. The inflammatory menu’s real product is a monitoring loop, and a vendor should sell it that way — paired baseline and follow-up results, not single tests.
Reasoning. A single CRP in an emergency case is often redundant with the clinical picture; the value emerges when the same patient is measured again after 48 hours of therapy. Vendors that market acute-phase proteins as diagnostic tests compete with clinical judgement and lose. Vendors that market them as a follow-up instrument are selling something no examination can provide: an objective measure of whether the treatment is working. That framing also aligns the commercial incentive with good practice, because it makes repeat testing the intended use rather than an upsell.
Disclosure. Written from published veterinary acute-phase protein literature; no new experimental data. Values marked are placeholders for Migibio’s platform data.
Related pages
- Canine C-reactive protein · Feline serum amyloid A
- Canine pancreatitis · Feline pancreatitis · Feline inflammation
- Sample handling · Reference intervals
Sources
- Reference to be added.
- Reference to be added.
- CLSI EP28-A3c — reference interval methodology.
Frequently asked questions
- Which acute-phase protein should be used in dogs and which in cats?
- In dogs, C-reactive protein is the major acute-phase responder and the practical choice. In cats, serum amyloid A carries the dominant response while CRP rises modestly. Using a canine marker in a cat and interpreting it with canine expectations understates the inflammatory response.
- Does a normal acute-phase protein exclude inflammation?
- No. Localized, walled-off, chronic low-grade and central nervous system inflammation can sit inside the reference interval. A normal value argues against a large systemic response; it does not exclude disease.
- How useful is a single value compared with a trend?
- The trend is usually more informative. Magnitude tells you how much inflammation exists at one moment; the change between two values, interpreted against the assay's imprecision, tells you whether the process is resolving or progressing — which is what treatment decisions usually need.